Milestone Pharmaceuticals announced that its etrapamil nasal spray to treat paroxysmal supraventricular tachycardia has been approved by the China National Drug Administration, marking the first time that etripamil has received regulatory approval outside the US.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.